Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

National Cancer Institute

- PMLiVE

AZ and EU fail to solve COVID-19 vaccine delivery issues

AZ temporarily reduced Q1 deliveries to the EU last week

- PMLiVE

AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly

German media reports suggested vaccine is less than 10% effective in the elderly

- PMLiVE

AstraZeneca reduces initial COVID-19 vaccine deliveries to the EU

Deliveries in the first quarter have been cut by 60%

- PMLiVE

The heavy toll of COVID-19 on cancer patients

We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Blue Latitude Health

- PMLiVE

Trial combining British and Russian COVID-19 vaccines could begin in February

AstraZeneca announced the clinical trial programme in December

- PMLiVE

Lilly partners with Merus on development of bispecific antibodies for cancer

As part of the deal, Merus could receive a total of up to around $1.6bn for three products

- PMLiVE

GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours

Investigational PD-1 inhibitor is being studied in mismatch repair-deficient solid tumours

- PMLiVE

Live Webinar: COVID-19 Has Changed Live Events Forever!

We invite you to join Impetus Digital and the Medical Affairs Professional Society (MAPS) on February 19, 10 am EST, for a thought-provoking webinar around the future of virtual events.

Impetus Digital

- PMLiVE

New dosing option for AZ’s Imfinzi approved in the EU and UK

Additional option extends dosing from two weeks to four weeks

- PMLiVE

AstraZeneca’s focus on diagnosing and managing chronic kidney disease

People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care

- PMLiVE

AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine

CHMP could reach a decision on opinion by 29 January

- PMLiVE

bluebird bio to separate oncology and rare diseases units

New oncology company will be led by current bluebird bio CEO Nick Leschly

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links